Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 13/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12945294 | 0.93 | CYP2E1 (0.35) | NR1I2RAF1CYP2E1MAPK14MAPK13 | |
| SCHEMBL12945299 | 0.93 | CYP2E1 (0.35) | NR1I2RAF1CYP2E1MAPK14MAPK13 | |
| SCHEMBL12945375 | 0.91 | NR1I2 (0.42) | NR1I2CYP2E1 | |
| SCHEMBL12945483 | 0.91 | NR1I2 (0.42) | NR1I2CYP2E1 | |
| SCHEMBL12945301 | 0.91 | NR1I2 (0.32) | NR1I2RAF1CYP2E1MAPK14 | |
| SCHEMBL173156 | 0.89 | NR1I2 (0.37) | NR1I2RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12909985 | 0.87 | NR1I2 (0.49) | NR1I2CYP2E1 | |
| SCHEMBL173100 | 0.87 | RAF1 (0.38) | NR1I2RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12945313 | 0.87 | RAF1 (0.38) | NR1I2RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12949453 | 0.87 | RAF1 (0.38) | NR1I2RAF1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885RAF1 1470/4885CYP2E1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.